Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07587775 · ClinicalTrials.gov registry record · Phase 2
The Effect of Osteoporotic Medications on Vertebral Bone Quality Score
A Phase 2 study, sponsored by State University of New York at Buffalo.
- Not yet
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07587775 is a Phase 2 study that has not yet begun recruiting, run by State University of New York at Buffalo. The registered enrollment target is 60 participants.
The verdict
NCT07587775, a Phase 2 study, has not yet begun recruiting, sponsored by State University of New York at Buffalo.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine the change in VBQ score, T score, TBS, and Hounsfield Units (HU) after 3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease. The main question\[s\] it aims to answer is: Does abaloparatide improve bone density in these patients, as defined by VBQ score compared to traditional methods such as DEXA and Hounsfield Units Does abaloparatide reduce the incidence of postoperative mechanical complications, including adjacent segment disease, subsidence, and proximal junctional kyphosis (PKJ)? Participants will undergo a presurgical assessments and trained in clinic on the subcutaneous application of abaloparatide. Prior to treatment, patients will have baseline assessments, including a lumbar MRI, DEXA scan, and lumbar CT. Post-surgically, participants will administer abaloparatide and return to clinic after 3-6 months for follow-up assessments including a new MRI, lumbar CT, and DEXA scan. Patients will be followed for up to 2 years postoperatively to identify complications such as adjacent segment disease, pseudarthrosis, failure of instrumentation, and PJK.
Interventions
- DRUG Abaloparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07587775
The ClinicalTrials.gov registry entry for NCT07587775 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abaloparatide is the first listed.
NCT07587775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07587775 about?
NCT07587775 is a clinical study titled "The Effect of Osteoporotic Medications on Vertebral Bone Quality Score". The goal of this clinical trial is to determine the change in VBQ score, T score, TBS, and Hounsfield Units (HU) after 3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease. The main question\[s\] it aims ...
What is the current status of trial NCT07587775?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-06-01. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07587775?
The interventions under investigation include: Abaloparatide (DRUG).
Who is sponsoring clinical trial NCT07587775?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.